Scipio bioscience is a French biotech startup developing, manufacturing and selling laboratory kits and analysis software for single-cell RNA sequencing (scRNA-seq). Single-cell sequencing is a most promising technology which greatly enhances possibilities of existing bulk genomic sequencing. Our goal is to enable all life-science researchers to easily access this new single-cell technology by breaking down the technical, logistical, and financial barriers through scientific innovation.
Scipio bioscience is backed by leading VCs (Seventure, M Ventures, HTGF, Verve Ventures, Arbevel) after 2 financing rounds: 1.5m€ seed in September 2017 and 6m€ Series A in January 2020. We are based in Paris 14 (at the hospital Cochin within the Paris Biotech Santé incubator) and our business language is English.
Our first commercial solution, based on an innovative proprietary method, has been announced at the Festival of Genomics & Biodata last January (watch our CEO’s presentation here). It consists of the Asteria benchtop kit for sample preparation and the Cytonaut cloud-based software service for analysis of sequencing results.